Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
62.93
-6.24 (-9.02%)
At close: Mar 30, 2026, 4:00 PM EDT
63.34
+0.41 (0.65%)
Pre-market: Mar 31, 2026, 4:13 AM EDT
Boston Scientific Revenue
In the year 2025, Boston Scientific had annual revenue of $20.07B with 19.87% growth. Boston Scientific had revenue of $5.29B in the quarter ending December 31, 2025, with 15.90% growth.
Revenue (ttm)
$20.08B
Revenue Growth
+19.88%
P/S Ratio
4.66
Revenue / Employee
$340,237
Employees
59,000
Market Cap
93.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.07B | 3.33B | 19.87% |
| Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
| Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
| Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
| Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
| Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
| Dec 31, 2019 | 10.74B | 912.00M | 9.28% |
| Dec 31, 2018 | 9.82B | 775.00M | 8.57% |
| Dec 31, 2017 | 9.05B | 662.00M | 7.89% |
| Dec 31, 2016 | 8.39B | 909.00M | 12.16% |
| Dec 31, 2015 | 7.48B | 97.00M | 1.31% |
| Dec 31, 2014 | 7.38B | 237.00M | 3.32% |
| Dec 31, 2013 | 7.14B | -106.00M | -1.46% |
| Dec 31, 2012 | 7.25B | -373.00M | -4.89% |
| Dec 31, 2011 | 7.62B | -184.00M | -2.36% |
| Dec 31, 2010 | 7.81B | -382.00M | -4.67% |
| Dec 31, 2009 | 8.19B | 138.00M | 1.71% |
| Dec 31, 2008 | 8.05B | -307.00M | -3.67% |
| Dec 31, 2007 | 8.36B | 536.00M | 6.85% |
| Dec 31, 2006 | 7.82B | 1.54B | 24.48% |
| Dec 31, 2005 | 6.28B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories | 44.33B |
| Medtronic | 35.48B |
| Stryker | 25.12B |
| Koninklijke Philips | 20.94B |
| GE HealthCare Technologies | 20.63B |
| Zimmer Biomet Holdings | 8.23B |
| Smith & Nephew | 6.16B |
| Edwards Lifesciences | 6.07B |
BSX News
- 16 hours ago - Boston Scientific Drops Despite Encouraging Trial Readouts - Benzinga
- 20 hours ago - Boston Scientific announces conference call discussing first quarter 2026 results - PRNewsWire
- 2 days ago - Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and Expo Transcript - Seeking Alpha
- 2 days ago - CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints - PRNewsWire
- 2 days ago - HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism - PRNewsWire
- 6 days ago - Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade) - Seeking Alpha
- 13 days ago - Invesco Summit Fund Q4 2025 Portfolio Positioning - Seeking Alpha
- 18 days ago - BSX Lawsuit Alleges Claims Executives Misrepresented U.S. Electrophysiology Volumes - BOSTON SCIENTIFIC CORPORATION Investors Face Losses Following Claims Executives Misrepresented U.S. Electrophysiology Volumes: SueWallSt - PRNewsWire